Sign up
Pharma Capital

Amarantus Bioscience moves HQ to Wall Street to raise more capital

The biotech company is developing treatments for Parkinson's disease and Alzheimer's disease
Scientist in a lab
The biotech company moved to a WeWork space in New York City

Amarantus Bioscience Holdings Inc. (OTCMKTS:AMBS)  will be moving its headquarters to New York in an effort to raise more capital.

The biotech company develops therapeutic products to treat neurological, psychiatric, ophthalmological and degenerative disorders like Parkinson’s disease and Alzheimer’s disease.

The company recently relocated to New York from San Francisco.

CEO Gerald Commissiong told Proactive Investors on Tuesday that the company’s central nervous system asset is moving into Phase 2B trials later this year.

There will be 60 to 80 participants in the study before moving onto the third phase.

Amarantus has a market cap of US$2.97mln.

Register here to be notified of future AMBS Company articles
View full AMBS profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.